Pharmacoeconomics Research Unit, Clinical Pharmacy Department, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Saudi Pharm J. 2012 Jul;20(3):187-94. doi: 10.1016/j.jsps.2011.12.006. Epub 2011 Dec 24.
In pharmacoeconomics the costs and consequences of alternative medications are compared. Many countries have begun to use pharmacoeconomic evidence to support decisions on licensing, pricing, reimbursement, or addition to the formulary. In Saudi Arabia, it is not mandatory to submit cost effectiveness evidence to support licensing or addition to the formulary decisions however, data will be considered if submitted. Previous evidence suggests that the use of pharmacoeconomic evidence by Saudi Pharmacy and Therapeutic (P&T) committee members in formulary decisions making process is limited mainly because of lack of expertise and lack of resources. This paper intended to provide Saudi P&T decision makers with a clear set of best practice methodological recommendations to help in increasing the utilisation of pharmacoeconomic evidence in the formulary decisions making process.
在药物经济学中，比较了替代药物的成本和结果。许多国家已经开始使用药物经济学证据来支持关于许可、定价、报销或纳入处方集的决策。在沙特阿拉伯，提交成本效益证据来支持许可或纳入处方集决策并非强制性的，但是如果提交，数据将被考虑。先前的证据表明，沙特药品和治疗学（P&T）委员会成员在处方集决策制定过程中使用药物经济学证据的情况有限，主要是因为缺乏专业知识和资源。本文旨在为沙特 P&T 决策者提供一套明确的最佳实践方法学建议，以帮助增加药物经济学证据在处方集决策制定过程中的使用。
